Vittorio Signori
2004-04-10 08:55:31 UTC
Lo dice la vostra scienza. Dunque, aggiornatevi.
--------------------------------------
Anticancer Drugs. 2003 Sep;14(8):585-8.
TT-232: a somatostatin structural derivative as a potent antitumor drug
candidate.
Szende B, Keri G.
First Department of Pathology and Experimental Cancer Research, Semmelweis
University, Molecular Pathology Research Group Joint Research Organisation
of the Hungarian Academy of Sciences and Semmelweis University, Budapest,
Hungary. ***@korb1.sote.hu
TT-232 (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) has been developed as an
antitumor somatostatin analog. TT-232 has no growth hormone release
inhibitory effect and does not inhibit the secretion of gastric acid. This
analog induces apoptosis in and exerts pronounced antiproliferative effects
on various human tumors (colon, pancreas, lymphoma, leukemia, melanoma,
hepatoma) cell lines. The growth of human xenografts (prostate, breast
carcinoma, lymphoma, melanoma) and animal tumors (colon-26, P-388, S-180,
B16, MXT) was inhibited by TT-232 (dose range: 30-750 microg/kg/day) in
54-98% of cases. Continuous long-term infusion proved to be the most
effective way of administration. TT-232 combined with decarbazine or
etoposide treatment enhanced the antitumor activity of these drugs on human
melanoma and lymphoma xenografts, respectively. Regarding the mode of
action, TT-232 activates cell cycle inhibitors via SSTR receptors, inhibits
tyrosine kinases through interfering with the proliferative signaling
cascades, and interacts with an intracellular receptor and an enzyme
involved in glycolysis causing translocation of this enzyme to the nucleus,
thus inducing apoptosis. TT-232 may be a promising candidate in the therapy
of human malignancies.
--------------------------------
Inviato via http://arianna.libero.it/usenet/
--------------------------------------
Anticancer Drugs. 2003 Sep;14(8):585-8.
TT-232: a somatostatin structural derivative as a potent antitumor drug
candidate.
Szende B, Keri G.
First Department of Pathology and Experimental Cancer Research, Semmelweis
University, Molecular Pathology Research Group Joint Research Organisation
of the Hungarian Academy of Sciences and Semmelweis University, Budapest,
Hungary. ***@korb1.sote.hu
TT-232 (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) has been developed as an
antitumor somatostatin analog. TT-232 has no growth hormone release
inhibitory effect and does not inhibit the secretion of gastric acid. This
analog induces apoptosis in and exerts pronounced antiproliferative effects
on various human tumors (colon, pancreas, lymphoma, leukemia, melanoma,
hepatoma) cell lines. The growth of human xenografts (prostate, breast
carcinoma, lymphoma, melanoma) and animal tumors (colon-26, P-388, S-180,
B16, MXT) was inhibited by TT-232 (dose range: 30-750 microg/kg/day) in
54-98% of cases. Continuous long-term infusion proved to be the most
effective way of administration. TT-232 combined with decarbazine or
etoposide treatment enhanced the antitumor activity of these drugs on human
melanoma and lymphoma xenografts, respectively. Regarding the mode of
action, TT-232 activates cell cycle inhibitors via SSTR receptors, inhibits
tyrosine kinases through interfering with the proliferative signaling
cascades, and interacts with an intracellular receptor and an enzyme
involved in glycolysis causing translocation of this enzyme to the nucleus,
thus inducing apoptosis. TT-232 may be a promising candidate in the therapy
of human malignancies.
--------------------------------
Inviato via http://arianna.libero.it/usenet/